Technical Analysis for PRTA - Prothena Corporation plc
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 20.57 | -2.05% | -0.43 |
Earnings due: Apr 29
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | -2.05% | |
| NR7 | Range Contraction | -2.05% |
| Alert | Time |
|---|---|
| Fell Below Lower Bollinger Band | about 10 hours ago |
| Possible NR7 | about 11 hours ago |
| Fell Below Previous Day's Low | about 15 hours ago |
| Down 2 % | about 15 hours ago |
| Down 1% | about 15 hours ago |
Get a Trading Sidekick!
- Earnings date: 04/29/2024
Prothena Corporation plc Description
Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, chronic traumatic encephalopathy, and other tauopathies; AÃ, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegeneration. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biology Disease Antibodies Neuroscience Alzheimer's Disease Parkinson's Disease Neurological Disorders Dementia Psychiatric Diagnosis Amyotrophic Lateral Sclerosis Amyloid Neurodegeneration Aging Associated Diseases Lewy Body Dementia Treatment Of Alzheimer's Disease Histopathology Frontotemporal Dementia Alpha Synuclein
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 79.64 |
| 52 Week Low | 20.44 |
| Average Volume | 631,950 |
| 200-Day Moving Average | 41.18 |
| 50-Day Moving Average | 26.11 |
| 20-Day Moving Average | 23.65 |
| 10-Day Moving Average | 22.38 |
| Average True Range | 1.35 |
| RSI (14) | 28.57 |
| ADX | 18.67 |
| +DI | 14.49 |
| -DI | 27.17 |
| Chandelier Exit (Long, 3 ATRs) | 22.39 |
| Chandelier Exit (Short, 3 ATRs) | 24.50 |
| Upper Bollinger Bands | 26.85 |
| Lower Bollinger Band | 20.46 |
| Percent B (%b) | 0.02 |
| BandWidth | 27.03 |
| MACD Line | -1.55 |
| MACD Signal Line | -1.35 |
| MACD Histogram | -0.1959 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 21.80 | ||||
| Resistance 3 (R3) | 21.89 | 21.58 | 21.60 | ||
| Resistance 2 (R2) | 21.58 | 21.26 | 21.53 | 21.53 | |
| Resistance 1 (R1) | 21.07 | 21.07 | 20.92 | 20.98 | 21.46 |
| Pivot Point | 20.76 | 20.76 | 20.68 | 20.71 | 20.76 |
| Support 1 (S1) | 20.25 | 20.44 | 20.10 | 20.16 | 19.68 |
| Support 2 (S2) | 19.94 | 20.25 | 19.89 | 19.61 | |
| Support 3 (S3) | 19.43 | 19.94 | 19.55 | ||
| Support 4 (S4) | 19.34 |
